ADP receptor P2Y12 is the capstone of the cross-talk between Ca
ADP
NAADP
P2 purinergic receptor (P2Y12
P2Y1)
SERCA3
blood platelets
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
14
06
2022
revised:
10
11
2022
accepted:
14
11
2022
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Blood platelet Ca The aim of this study was to identify which ADP P2 purinergic receptor (P2Y1 and/or P2Y12) is(are) involved in the amplification of platelet secretion dependent on the SERCA3-dependent Ca The study used the pharmacologic antagonists MRS2719 and AR-C69931MX, of the P2Y1 and P2Y12, respectively, as well as We found that in mouse platelets, pharmacological blockade or gene inactivation of P2Y12 but not of P2Y1 led to a marked inhibition of ADP secretion after platelet stimulation with low concentration of thrombin. Likewise, in human platelets, pharmacological inhibition of P2Y12 but not of P2Y1 alters amplification of thrombin-elicited secretion through SERCA2b stores mobilization. Finally, we show that early SERCA3 stores secretion of ADP is a dense granule secretion, based on parallel adenosine triphosphate and serotonin early secretion. Furthermore, early secretion involves a single granule, based on the amount of adenosine triphosphate released. Altogether, these results show that at low concentrations of thrombin, SERCA3- and SERCA2b-dependent Ca
Sections du résumé
Background
UNASSIGNED
Blood platelet Ca
Objectives
UNASSIGNED
The aim of this study was to identify which ADP P2 purinergic receptor (P2Y1 and/or P2Y12) is(are) involved in the amplification of platelet secretion dependent on the SERCA3-dependent Ca
Methods
UNASSIGNED
The study used the pharmacologic antagonists MRS2719 and AR-C69931MX, of the P2Y1 and P2Y12, respectively, as well as
Results
UNASSIGNED
We found that in mouse platelets, pharmacological blockade or gene inactivation of P2Y12 but not of P2Y1 led to a marked inhibition of ADP secretion after platelet stimulation with low concentration of thrombin. Likewise, in human platelets, pharmacological inhibition of P2Y12 but not of P2Y1 alters amplification of thrombin-elicited secretion through SERCA2b stores mobilization. Finally, we show that early SERCA3 stores secretion of ADP is a dense granule secretion, based on parallel adenosine triphosphate and serotonin early secretion. Furthermore, early secretion involves a single granule, based on the amount of adenosine triphosphate released.
Conclusion
UNASSIGNED
Altogether, these results show that at low concentrations of thrombin, SERCA3- and SERCA2b-dependent Ca
Identifiants
pubmed: 36970741
doi: 10.1016/j.rpth.2022.100004
pii: S2475-0379(22)01100-1
pmc: PMC10031336
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100004Informations de copyright
© 2022 The Author(s).
Références
Blood. 2016 Nov 24;128(21):2538-2549
pubmed: 27625359
Br J Haematol. 1997 Apr;97(1):192-203
pubmed: 9136965
J Biol Chem. 2004 Jun 4;279(23):24297-306
pubmed: 15028735
Circ Res. 2020 Sep 11;127(7):e166-e183
pubmed: 32588751
J Biol Chem. 1992 Jul 15;267(20):14483-9
pubmed: 1385815
Am J Physiol. 1982 Sep;243(3):R454-61
pubmed: 7114301
Platelets. 2005 May-Jun;16(3-4):133-50
pubmed: 16011958
Blood. 2016 Aug 25;128(8):1129-38
pubmed: 27301859
Biochem J. 1993 Apr 1;291 ( Pt 1):235-40
pubmed: 8385934
J Thromb Haemost. 2009 Jul;7(7):1057-66
pubmed: 19422456
J Biol Chem. 1997 Nov 28;272(48):30538-45
pubmed: 9374548
Biochim Biophys Acta. 2009 Feb;1793(2):223-30
pubmed: 19061922
Blood. 2007 Feb 15;109(4):1503-6
pubmed: 17032923
Blood. 2005 May 1;105(9):3552-60
pubmed: 15665114
Biochem Soc Trans. 2015 Jun;43(3):502-7
pubmed: 26009198
J Biol Chem. 1994 Jan 14;269(2):1410-6
pubmed: 8288608
Biochem J. 1996 Sep 1;318 ( Pt 2):689-99
pubmed: 8809064
Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1164-73
pubmed: 27079884
J Thromb Haemost. 2015 Jun;13 Suppl 1:S10-6
pubmed: 26149010
Adv Exp Med Biol. 2016;898:333-52
pubmed: 27161235
Annu Rev Pharmacol Toxicol. 2006;46:277-300
pubmed: 16402906
J Biol Chem. 2002 Jan 25;277(4):2965-72
pubmed: 11713259
Adv Exp Med Biol. 2017;993:139-157
pubmed: 28900913
Thromb Haemost. 2019 Mar;119(3):384-396
pubmed: 30650444
Handb Exp Pharmacol. 2012;(210):59-85
pubmed: 22918727
Biochem Pharmacol. 2008 Jun 1;75(11):2157-64
pubmed: 18439569
Biochem J. 1992 Aug 15;286 ( Pt 1):135-40
pubmed: 1387787
Purinergic Signal. 2011 Sep;7(3):293-303
pubmed: 21792575
Cell Signal. 2006 Mar;18(3):373-81
pubmed: 16095882
Nature. 2002 Aug 8;418(6898):605-11
pubmed: 12167852